6533b860fe1ef96bd12c2ff1

RESEARCH PRODUCT

Corrigendum to “The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update” [Respiratory Medicine 103 (2009) 1098–1113]

Z. PanahlooPablo JimenezRoland BuhlStephen T. HolgateJean BousquetNicola Smith

subject

Respiratory MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryResearch centreFamily medicineMedicineAllergic asthmaOmalizumabGeneral hospitalbusinessUniversity hospitalmedicine.drug

description

a Infection, Inflammation and Repair Division, School of Medicine, University of Southampton, D level Centre Block (MP810), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK Mainz University Hospital, 55131 Mainz, Germany Hopital Arnaud de Villeneuve, FR-34000 Montpellier, France Novartis Horsham Research Centre, Horsham, RH12 5AB, UK Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936-1080, USA

yearjournalcountryeditionlanguage
2010-06-01Respiratory Medicine
10.1016/j.rmed.2010.04.008http://dx.doi.org/10.1016/j.rmed.2010.04.008